A PYMNTS Company

Australia : Nurofen facing $6m headache for misleading consumers

By  |  April 13, 2016

Nurofen ‘should be fined’ $6million for ‘misleading’ shoppers by selling a range of ‘pain-targeted’ tablets which are exactly the same and cost twice as much at the standard range, a watchdog said.

The drug’s maker, Reckitt Benckiser, has lost a court battle against the Australian Competition and Consumer Commission (ACCC) over the ‘pain specific’ products.

The tablets, which promised to ease tension headaches, back pain, migraine pain and period pain, have been removed from Australian shelves over the past three months.

All of the products contained the same active ingredient, ibuprofen lysine 342mg, and each had the same effect on pain, the ABC reported.

Full Content: The Guardian

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.